The press release below was prepared by the American Association for Cancer Research. View the original here. Next-generation sequencing for minimal residual disease was highly sensitive and more ...
The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival ...
Minimal residual disease (MRD) monitoring in childhood and adult acute myeloid leukemia (AML) using flow cytometry is still under discussion in terms of the prognostic impact, the optimal time points ...
Underuse of Breast Cancer Adjuvant Treatment: Patient Knowledge, Beliefs, and Medical Mistrust Speed of blast clearance is an indicator of outcome in childhood acute lymphoblastic leukemia (ALL).
In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: ...
Why minimal residual disease testing is the "gold standard" for some patients and providers. When Michael Ray went to his doctor for an annual checkup two years ago, he felt fine. But the bloodwork ...
Please could you both introduce yourselves and give a brief outline of your roles at Cerba Research? ADB: My name is Ans De Beuckelaer. I have a Ph.D. in biotechnology from the University of Ghent. In ...
Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...
Please provide your email address to receive an email when new articles are posted on . Chimeric antigen receptor T-cell therapy targeting CD19 is highly effective for inducing remission among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback